Why the study?
Should new drug development in heart failure focus on patients discharged from an acute heart failure admission?
Should new drug development in heart failure focus on patients discharged from an acute heart failure admission?
This editorial discusses the potential benefits of shifting heart failure drug development focus toward patients recently discharged from an acute admission to accelerate the delivery and implementation of new interventions.
Over more than 30 years, most drug development in heart failure (HF) has been directed towards reducing HF readmission or death in patients with chronic heart failure (1-3). These studies included thousands of patients and took many years to accomplish but permitted approval of new interventions that substantially improved HF patients’ outcomes. However, the long duration of HF mega studies leads to substantial delays in delivering these new interventions, and hence delays their implementation and uptake.
No takes yet. Share an insight, caveat, or question.
Cotter et al. (2023) conducted an editorial in Heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: